基于网络药理学分析续断-骨碎补治疗原发性骨质疏松症的作用机制OA

Objective To explore the mechanism of continuan-Drynaria fortunei in the treatment of primary osteoporosis based on network pharmacology.Methods The active ingredients and action targets of Drynaria continua were collected through the Chinese Medicine System Pharmacology Database and Analysis Platform(TCMSP)database.The relevant targets of primary osteoporosis were screened out by using the OMIM database,Genecards database,DrugBank database and DisGeNet database.Take the intersection of the target of the drug and the disease to obtain the target where the drug directly acts on the disease.The intersection targets were imported into the String database for protein-protein interaction(PPI)analysis.Visualization was performed using Cytoscape v3.10.2,and topological parameters were calculated to select the core targets..The core targets were imported into the metascape database for gene ontology(GO)enrichment analysis and Kyoto Encyclopedia of Genes and Genomes(KEGG)signaling pathway enrichment analysis.Results 22 active components of traditional Chinese medicine and 331 potential targets of Drynaria fortunei were screened out,as well as 7237 targets related to primary osteoporosis.There were a total of 244 intersection targets between the drug and the disease.The continuous discontinuation of bone Shatteria drug regulates targets such as AKT1,ESR1,HSP90AA1,EGFR,SRC,PIK3CA,and PTGS2.The intervention covers related signaling pathways such as the cancer pathway,cAMP signaling pathway,cellular senescence pathway,neuroactive ligand-receptor interaction pathway,arachidonic acid metabolism pathway,and Th17 cell differentiation pathway,thereby achieving the therapeutic effect on primary osteoporosis.Conclusion This study predicted the main active ingredients,targets and enrichment pathways of Drynaria fortunei in the treatment of primary osteoporosis through network pharmacology,providing a scientific basis for its in-depth clinical research.